Gerresheimer stock steadies as interim CEO steps down and portfolio reshaping accelerates

Gerresheimer stock is trading in the mid-20s EUR range as investors digest the exit of interim CEO Uwe Röhrhoff and asset sales tied to a broader transformation program, alongside growing revenue and margin ambitions.

Gerresheimer AG (ISIN DE000A0LD6E6) stock is trading in the mid-20s EUR range as of August 28, 2026, with investors weighing the announced exit of interim CEO Uwe Röhrhoff and significant portfolio reshaping moves including planned disposals and recent acquisitions.

The company has come back into focus with agreements to sell its Centor and Primary Packaging Plastics businesses for €1.5 billion and updated early 2026 figures that show continued growth and an emphasis on cash generation.

For equity holders, the combination of leadership change and a more focused portfolio sets the stage for a clearer earnings and margin story over the coming quarters.

Leadership change and short-term share reaction

According to a personnel announcement dated August 24, 2026, interim CEO Uwe Röhrhoff is ending his mandate, a move that arrives at a time when the group is already adjusting its structure through disposals and acquisitions. A same-day market overview shows Gerresheimer shares quoted at €26.62 with a daily gain of 0.38 percent linked to this management update.

In a separate coverage of recent trading, one early-quote snapshot on August 27, 2026 reported the stock at €25.33 with a slight decline of 0.12 percent, illustrating how the shares have oscillated within a tight range while the leadership transition has been digested.

Intraday order-book data from August 28, 2026 indicate trading levels between €25.64 and €25.94 on Xetra, underlining that the market is currently assigning Gerresheimer a mid-20s EUR price band rather than any extreme valuation swings.

Asset sales, revenue growth and margin ambitions

A detailed analytical piece on Gerresheimer dated August 29, 2026 highlights that the company has agreed to sell its Centor and Primary Packaging Plastics operations for €1.5 billion in total consideration, part of a broader transformation program aimed at sharpening its focus on higher-value pharmaceutical and medical packaging and solutions. The same analysis notes that this transaction is being evaluated against Gerresheimer's current valuation and long-term earnings potential.

The article points out that Gerresheimer generated revenues of €2 billion in 2024 and that the integration of the acquired Bormioli Pharma business is expected to lift revenues to €2.5 billion in 2025, an increase of €0.5 billion or 25 percent over the 2024 level. It further describes a target for the adjusted EBITDA margin to move toward 22 percent with this enlarged and more specialized portfolio, suggesting a margin expansion strategy as volume and mix shift into higher-value segments.

These numbers, tied to fiscal 2024 and 2025 expectations, provide a historical and near-term context rather than a full picture of 2026 performance, but they show that the company is working from a base of multi-billion-euro revenues and aiming to generate more profit per euro of sales as portfolio measures take effect.

For the first quarter of 2026, a German-language market-news article reports that Gerresheimer achieved revenue growth and highlighted free cash flow as a central focus, underscoring management's attention to cash generation during the transformation. One data table there lists a Gerresheimer share reference level of €26.45 linked with performance metrics, suggesting that the stock has been trading close to the mid-20s EUR zone throughout early 2026 while quarterly figures improved.

From an investor's perspective, the move to sell lower-margin assets and invest into higher-margin platforms, combined with clear targets for revenue and adjusted EBITDA margin, makes the cash-flow profile a key factor in assessing whether current valuation levels are justified.

Valuation, fair value estimates and recent performance

The analytical valuation piece dated August 29, 2026 sets a narrative fair value estimate for Gerresheimer at €25.26 and labels the shares as overvalued at the last close of €26.62. At that closing price, the stock trades 5.4 percent above this fair value estimate, based on long-term forecasts and upgraded assumptions embedded in the model.

The same article points to a 30-day share price return of 5.54 percent and a 7-day share price return of 3.55 percent, indicating positive but moderate recent momentum. These performance metrics suggest that the stock has delivered a mid-single-digit gain over the last month and week, roughly in line with a re-rating driven by restructuring news rather than a sharp speculative spike.

For valuation-focused investors, the comparison between the €26.62 last close and the €25.26 fair value estimate provides a concrete benchmark: the shares would need to fall by €1.36 to align exactly with the modelled fair value, or management would need to deliver earnings and margin outcomes above current expectations to justify the premium.

Against the backdrop of the €1.5 billion asset sale, the revenue trajectory from €2 billion in 2024 toward €2.5 billion in 2025, and the targeted adjusted EBITDA margin of 22 percent, this moderate premium can be read as the market pricing in some success of the transformation program while still leaving room for disappointment if execution falters.

Representative product: pharmaceutical packaging and Bormioli Pharma integration

Gerresheimer is best known for its pharmaceutical primary packaging and drug-delivery solutions, spanning glass vials, syringes, cartridges and plastic containers used by drugmakers worldwide. The acquisition and integration of Bormioli Pharma expands this offering with additional glass and plastic packaging lines for injectable and oral medicines, enhancing Gerresheimer's ability to serve global pharma clients with standardized, regulatory-compliant containers and closures.

By combining Gerresheimer's legacy portfolio with Bormioli Pharma's assets, the group aims to unlock synergies in manufacturing and distribution while providing customers with a broader catalogue of container types and volumes that can be tailored to specific therapeutic applications.

Gerresheimer stock and current trading context

As of August 28, 2026, Gerresheimer shares on Xetra are quoted in the mid-20s EUR range, with intraday order-book data showing executed trades around €25.64 and displayed offers up to €25.94, reflecting modest day-to-day volatility and reasonable liquidity.

The leadership transition involving interim CEO Uwe Röhrhoff, the planned €1.5 billion divestiture of Centor and Primary Packaging Plastics, and the revenue and margin ambitions following the Bormioli Pharma integration collectively frame the near-term narrative for Gerresheimer stock as investors track whether the transformation program translates into sustained earnings growth and stronger cash generation.

Fact box

Company: Gerresheimer AG

ISIN: DE000A0LD6E6

Ticker: GXI

Exchange: Xetra

Sector / Industry: Health care - medical supplies and pharmaceutical packaging